Hematology Oncology Research

Publications

Researchers within the UCLA Division of Hematology-Oncology routinely disseminate the findings of their impactful work through publications in top-tier journals. Keep up with their latest articles here.

July 2026

  1. Silverstein JF, Huppert LA, Schwede M, Goglin S, Johnson TP, Babik JM, Brondfield S. Optimizing a Hematology/Oncology Curriculum for Internal Medicine Residents: A Two-Institution Modified Delphi Study. J Cancer Educ. 2026 Jun 30. doi: 10.1007/s13187-026-02916-y. Epub ahead of print. PMID: 42380386.
  2. Choueiri TK, Merchan J, Patnaik A, Drakaki A, Rini BI, Rha SY, Lee JL, Ornstein MC, Kumar R, Hwang C, Shao Y, Park SH, Barata PC, McGregor BA, Foster P, Chen J, Eisen M, Cole H, Weeder B, Guan Y, Singh J, Kaplan A, Cho S, Markus R, Kabbarah O, McKay RR. Casdatifan shows durable response linked to HIF-2α biology in kidney cancer. Nature. 2026 Jul 1. doi: 10.1038/s41586-026-10718-x. Epub ahead of print. PMID: 42386974.
  3. Zhang S, Queen KJ, Duggirala N, Yang E, Lipsyc-Sharf M, Racz J, Bennett J, Hong K, Suresh Y, Hamilton C, Pitta M, Chien N, La E, Russell CA, Bardia A, Kapoor NS. Identifying the window of aggressive postpartum breast cancer based on the 21-gene Oncotype DX® test in women with HR+, HER2-negative breast cancer. NPJ Breast Cancer. 2026 Jul 1. doi: 10.1038/s41523-026-01002-2. Epub ahead of print. PMID: 42386766.
  4. O'Dwyer K, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, Damlaj M, Dholaria B, Dias AL, Dils A, Fritsch M, Greer J, Hayes-Lattin B, Henry M, Jaffe A, Jamy O, Kebriaei P, Mehrtens I, Shah NN, Wilde L, Young PA, Mai HJ, Kanaan G, Sereda Y, Saldanha IJ, Balk EM, Gupta S. American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults. Blood Adv. 2026 Jul 14;10(13):4726-4756. doi: 10.1182/bloodadvances.2021006479. PMID: 41670624.
  5. Hoff FW, Zeidner JF, Torlapati G, Nicolet D, Mrózek K, Huang Y, Li A, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Olin RL, Smith CC, Schiller GJ, Curran EK, Chan O, McMahon C, Hochman M, Sahasrabudhe K, Foucar C, Gonzalez-Lugo J, Knick Ragon B, Handa SV, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Eisfeld AK, Byrd JC, Madanat YF. Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA. Am J Hematol. 2026 Jul 2. doi: 10.1002/ajh.70419. Epub ahead of print. PMID: 42393840.
  6. Lachowiez CA, Zeidner JF, Othman J, Kaempf A, Yun S, Heiblig M, Heuser M, Shahswar R, Madero Marroquin R, Cannova JM, Žučenka A, Marvin-Peek J, Senapati J, Abaza Y, Swaroop A, Zacheo I, Monaco F, Belhabri A, Tauveron-Jalenques U, Tavernier E, Carré M, Aspas Requena G, Cook RJ, Traer E, Saultz JN, O'Nions J, Basheer F, Laurie J, Handa S, Stein EM, Baer MR, Olin R, Blum W, Schiller G, Lin T, Curran E, Yocum A, Madarang E, Daver N, Kadia TM, Marconi G, Madanat Y, Dillon R, DiNardo CD, Swords R, Arango Ossa JE, Watts J, Loghavi S, Pollyea DA, Bernard E; PRISM-AML Investigators. Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model. J Clin Oncol. 2026 Jul 2:JCO2600347. doi: 10.1200/JCO-26-00347. Epub ahead of print. PMID: 42391582.
  7. Singleton M, Plankey M, Bowleg L, Brock JB, Haberlen S, Jamieson BD, Kempf MC, Konkle-Parker DJ, Kwait J, Martinson J, Mimiaga MJ, Ramirez CM, Stosor V, Tsai AC, Turan JM, Ware D, Weiss DJ, Wu KC, Friedman MR. The Association Between Healthcare Provider Trust and Healthcare Avoidance: Findings From a HIV Mixed Serostatus Cohort Study. Am J Health Promot. 2026 Jul 8:8901171261468527. doi: 10.1177/08901171261468527. Epub ahead of print. PMID: 42420158.
  8. Shin SJ, Lee JL, Powles T, Martin-Liberal J, Morales-Barrera R, Drakaki A, Friedlander T, Joly F, Shah SA, Vuky J, Ianculescu I, Michielin F, Gan X, Bamias A. A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma). ESMO Open. 2026 Jul 8;11(8):108303. doi: 10.1016/j.esmoop.2026.108303. Epub ahead of print. PMID: 42418909.
  9. Heskett MB, Vouzas AE, Johnstone B, Freese KP, Yates PA, Copenhaver PF, Spellman PT, Gilbert DM, Thayer MJ. Autosomal allelic inactivation at loci with variable replication timing and dosage sensitivity. Elife. 2026 Jul 8;15:RP109938. doi: 10.7554/eLife.109938. PMID: 42417611; PMCID: PMC13345637.
  10. Macarulla T, Cid RP, Womack MS, Gracian AC, Zervoudakis A, Hatoum H, Chung V, Patel A, Paulson AS, Pant S, O'Reilly EM, Hubner RA, Van Cutsem E, Bekaii-Saab T, Zhang L, Li J, Chen H, Maxwell F, Wainberg ZA, Melisi D. Response to Letter to the Editor: 'NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial'. ESMO Open. 2026 Jul 9;11(8):108307. doi: 10.1016/j.esmoop.2026.108307. Epub ahead of print. PMID: 42424906.
  11. Modi S, Murthy RK, Chien AJ, Lin NU, McAndrew NP, Specht JM, Zelnak AB, Ramos J, Xie D, Ho J, Inoue JK, Carey LA, Hamilton EP. Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 Study. Clin Breast Cancer. 2026 Jul 10;26(8):21-30. doi: 10.1016/j.clbc.2026.05.010. Epub ahead of print. PMID: 42431148.
  12. Peters S, Meyer ML, André F, Argilés G, Azizi AA, Banerjee S, Burgers S, Curigliano G, Drago JZ, Fontana E, Garon EB, Klümper N, Le Bescond L, Lopez-Rios F, Mountzios G, Passaro A, Paz-Ares L, Pistilli B, Powles T, Reguart N, Remon J, Schmelzle T, Skynner MJ, Smit E, Smyth E, Swanton C, Van Cutsem E, Loi S, Stahel RA. Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation. ESMO Open. 2026 Jul 10;11(8):108316. doi: 10.1016/j.esmoop.2026.108316. Epub ahead of print. PMID: 42431135.
  13. Tan CR, Gordan L, Richter J, DiLeo R, Mewawalla P, Larson S, Davies F, Oveisi D, Gupta-Werner N, Medhekar R, Yin X, Cortoos A, Armoon M, Thompson-Leduc P, Rahman A, Tardif-Samson A, Vanden Eynde C, Reitan J, Milkovich G, Bubalo J, Forman A, Bryan B, Sborov D, Kaila S, Usmani S. Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma. Future Oncol. 2026 Jul 14:1-9. doi: 10.1080/14796694.2026.2698699. Epub ahead of print. PMID: 42444515.
  14. Lipsyc-Sharf M, Hurvitz SA. Current Management of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in a Changing Landscape. J Clin Oncol. 2026 Jul 13:JCO2600672. doi: 10.1200/JCO-26-00672. Epub ahead of print. PMID: 42441937.
  15. Waks AG, Segui E, Li T, Lipsyc-Sharf M, Kallfelz E, DiLullo M, Patel A, Rahman T, Junkins K, Rahee H, Frey AM, Kelly E, Stalteri M, Wrabel E, Williams A, Parsons H, Poorvu PD, Partridge A, Abravanel DL, Poorvu N, LeStage B, Sicinski P, Tolaney SM, Wagle N, Tayob N, Shapiro GI. Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial. Clin Cancer Res. 2026 Jul 13. doi: 10.1158/1078-0432.CCR-26-0721. Epub ahead of print. PMID: 42440363.
  16. Goldberg SB, Ahn MJ, Baik C, De Castro Carpeño J, Cho BC, de Langen AJ, Fidler MJ, Goldman JW, Grønberg BH, Akamatsu H, Kim SW, Kim YJ, Le X, Marrone KA, Piotrowska Z, Riess JW, Shiraishi Y, Fraenkel PG, Merchan Ruiz B, Smith PE, Tang KH, Yu HA. Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD. Clin Cancer Res. 2026 Jul 13. doi: 10.1158/1078-0432.CCR-26-0704. Epub ahead of print. PMID: 42440354.
  17. Srour SA, Chahoud J, Drakaki A, Curti BD, Gibney GT, Tang L, Jiang Y, Charmsaz S, Robbins PB, McLeroy J, Severyn CJ, Le Gall JB, Roberts ZJ, Tannir NM, Pal S, Kotecha RR. Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial. J Clin Oncol. 2026 Jul 14:JCO2600388. doi: 10.1200/JCO-26-00388. Epub ahead of print. PMID: 42447427.
  18. Tai D, Kim KI, Shah P, Park D, Kim L, Li J, Jung C, Guzman S, Brar G, Wu S, Castillo D. Impact of metastatic pattern and histologic subtype on PD-(L)1 inhibitor efficacy in HER2-negative advanced gastric and gastroesophageal cancer: a meta-analysis. Front Oncol. 2026 Jun 29;16:1857990. doi: 10.3389/fonc.2026.1857990. PMID: 42444824; PMCID: PMC13357174.
  19. Schoen MW, Li J, Zeng S, Desai H, Hausler R, Haroldsen CL, Owens L, Valle LF, Etzoni RB, Rebbeck TR, Rose BS, Kelley MJ, Montgomery RB, Nickols NG, Rettig MB, Yamoah K, Maxwell KN, Garraway IP. Genomic Classification to Predict Survival in Metastatic Prostate Cancer: Development of Somatic Tumor Risk Assessment for Overall Survival-Prostate. JCO Precis Oncol. 2026 Jul;10(7):e2600021. doi: 10.1200/PO-26-00021. Epub 2026 Jul 15. PMID: 42456085.
  20. Ravani LV, Bagheri Z, Kalinsky K, Burstein HJ, Bardia A, Mouabbi JA, O'Regan R, Wander SA. Progression-Free Survival in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review: A Systematic Review and Meta-Analysis. JAMA Oncol. 2026 Jul 16. doi: 10.1001/jamaoncol.2026.1571. Epub ahead of print. PMID: 42461660.
  21. Himmelstein GE, Ganz PA. Are age and sex associated with variation in use of follow-up care and financial barriers to care in U.S. cancer survivors? J Cancer Surviv. 2026 Jul 17. doi: 10.1007/s11764-026-02076-4. Epub ahead of print. PMID: 42469517.
  22. Gee CM, Evans MB, Sinden AR, Shirazipour CH, Martin Ginis KA, Latimer-Cheung AE. Exploring Features of the Parasport Environment Associated With Quality Participation. Adapt Phys Activ Q. 2026 Jul 16:1-10. doi: 10.1123/apaq.2025-0099. Epub ahead of print. PMID: 42468925.
  23. Owen RG, McCarthy H, D'Sa S, Thomas SK, Tournilhac O, Forconi F, Kersten MJ, Zinzani PL, Iyengar S, Kothari J, Minnema MC, Kastritis E, Cheson BD, Walter HS, Greenwald D, Calvo R, Li Y, Rule S, Furman RR. Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up. Blood Adv. 2026 Jul 28;10(14):5058-5069. doi: 10.1182/bloodadvances.2025017713. PMID: 41985004.
  24. Carlson SG, Puliafito BR, Kawai K, Senaratne TN, Lee TD, Lin T, Timmerman J, Larson SM. Impact of clonal hematopoiesis of indeterminate potential on treatment outcomes in multiple myeloma patients undergoing CAR-T cell therapy. Int J Hematol. 2026 Jul 18. doi: 10.1007/s12185-026-04249-4. Epub ahead of print. PMID: 42470580.
  25. Zaikos TD, Pham V, Chou TC, Moran JA, Turner SR, Yu BH, Hourani R, Ranjan A, Zack JA, Wender PA, Marsden MD. PKC inhibitors reveal PKC isoforms involved in HIV latency reversal and immunomodulation. J Virol. 2026 Jul 20:e0050026. doi: 10.1128/jvi.00500-26. Epub ahead of print. PMID: 42474185.
  26. Brauer ER, Bastani R, Cheng E, Lazaro S, Wong DJ, St John MA, Ganz PA. Using electronic patient reported outcomes (ePROs) to improve supportive care in ambulatory oncology care: a CFIR-guided pre-implementation formative evaluation. J Patient Rep Outcomes. 2026 Jul 21. doi: 10.1186/s41687-026-01144-8. Epub ahead of print. PMID: 42479244.
  27. Valle LF, Scobie M, Rowe K, Pritchard CC, Montgomery B, Garraway IP, Nickols NG, Schoen MW, Kishan AU, Kelley MJ, Rettig MB, Maxwell KN. Interference of Clonal Hematopoiesis in cfDNA Liquid Biopsy Testing & Identification of Actionable Alterations in Large Diverse Cohort of US Veterans. Oncologist. 2026 Jul 21:oyag265. doi: 10.1093/oncolo/oyag265. Epub ahead of print. PMID: 42479142.
  28. Niknafs AM, Damron LF, Baclig NV, Iliopoulos M, Drakaki A. Threading the Needle in Bladder Cancer: A Narrative Review of the Emerging Role of Integrative Oncology in Treatment-Related Adverse Events in the Era of Immunotherapy and Antibody-Drug Conjugates. Cureus. 2026 Jun 22;18(6):e111294. doi: 10.7759/cureus.111294. PMID: 42488263; PMCID: PMC13390731.
  29. Skoulidis F, Jabbour SK, Garon EB, Iyengar P, Scagliotti G, Ferrer L, Etchepare G, Gallinato O, Faure J, Bernard P, Colin T, Menu P, Lin Y, Cai L, Chaudhry AA, Remorino A, Stewart R, Luciani-Silverman L, Miller K, Dellamonica D, Faria J, Zhang Y. Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT). Clin Cancer Res. 2026 Jul 22. doi: 10.1158/1078-0432.CCR-25-3729. Epub ahead of print. PMID: 42485106.
  30. Gong R, Wang L, Xue D, Cai J, Jiang Y, Huang J, Zhu J, Li Z, Ke A, Shi G, Wang J, Wang W, Zheng J, Yang W, Zhang Z, Zhou J, Fan J, Zhang W, Gao P, Chen L, Song D. cfDNA derived gene signatures as surrogate for microvascular invasion in HCC. JHEP Rep. 2026 Jul 21:101966. doi: 10.1016/j.jhepr.2026.101966. Epub ahead of print. PMID: 42480815.
  31. Vaghashia D, Sullivan P, Livhits MJ, Donangelo I, Laklouk I, Teshome M, Lipsyc-Sharf M. Neuroendocrine Tumor of the Breast in a Young Woman With MEN2A Syndrome. AACE Endocrinol Diabetes. 2026 Feb 21;13(4):617-621. doi: 10.1016/j.aed.2026.02.007. PMID: 42491478; PMCID: PMC13377883.
  32. Wainberg ZA, Lee KW, Kim JG, Devoe C, Strickler JH, Baum J, Jia C, Kagey MH, Sirard CA, Stein A, Scott AJ, Pelster M, Moehler M, Han SW. Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial. Clin Cancer Res. 2026 Jul 23. doi: 10.1158/1078-0432.CCR-26-1456. Epub ahead of print. PMID: 42489705.
  33. Graham DM, Lofftus S, Azizi L, Berkowitz MJ, Teshome M. The Role of Immunotherapy in Breast Cancer and Mechanisms of Immune Escape: What Surgeons Need to Know. Am Surg. 2026 Jul 24:31348261468304. doi: 10.1177/00031348261468304. Epub ahead of print. PMID: 42498515.
  34. Rugo HS, Jhaveri K, Pernas S, Pistilli B, Im SA, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Nowecki Z, Tolaney SM, Zhao K, Atuah K, Verma D, Xu B, Bardia A; TROPION-Breast01 investigators. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study. ESMO Open. 2026 Jul 24;11(8):108330. doi: 10.1016/j.esmoop.2026.108330. Epub ahead of print. PMID: 42497483.
  35. Tupper HI, Gao YA, Cummings AL. Lung Cancer Screening in California and Los Angeles County: A Landscape Analysis. Cureus. 2026 Jun 27;18(6):e111619. doi: 10.7759/cureus.111619. PMID: 42516477; PMCID: PMC13404923.
  36. Sonni I, Gulpe A, Nickols NG, Schaffer D, Montagut L, Berenji GR, Rettig MB. Early detection and localization of recurrent prostate cancer using [Formula: see text]F-DCFPyL PET/CT in patients with low and ultra-low PSA levels. EJNMMI Res. 2026 Jul 27;16(1):114. doi: 10.1186/s13550-026-01490-0. PMID: 42509445.
  37. Kishan AU, Sun Y, Parker CC, Sargos P, Sydes M, Chabaud S, Brihoum M, Supiot S, Latorzeff I, Guerif S, Kalbasi TR, Steinberg ML, Valle LF, Taparra K, Farrell MJ, Shoag JE, Garcia JA, Brown JR, Rettig MB, Singer AE, Baclig N, Reiter RE, Eggener S, Brisbane W, Roy S, Jia AY, Ma TM, Nickols NG, Efstathiou JA, Dignam JJ, Seiferheld WF, Pollack A, Sandler HM, Nguyen PL, Pommier P, Spratt DE. Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis. Eur Urol. 2026 Jul 28:S0302-2838(26)02270-0. doi: 10.1016/j.eururo.2026.07.013. Epub ahead of print. PMID: 42521517.
  38. Wierda WG, Dorritie KA, Gauthier J, Nath R, Kipps TJ, Riedell PA, Eradat HA, Kenderian SS, Kharfan-Dabaja MA, Shah NN, Solomon SR, Stephens DM, Ermann DA, Arnason JE, Deol A, Feldman TA, Andreadis CB, Ghosh M, Ma S, Schuster SJ, Gergis U, Vose JM, Soumerai JD, van Besien K, Tuazon SA, Perna SK, Ou SS, Ananthakrishnan R, Rane N, Papp E, Ansari S, Thompson EG, Okal A, Peiser L, Chen Y, Sengupta S, Ray PR, Wang J, Siddiqi T. Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004. Blood. 2026 Jul 28:blood.2026033565. doi: 10.1182/blood.2026033565. Epub ahead of print. PMID: 42520199.
  39. Borate UM, Huang Y, Lin TL, Handa S, Swords R, Lachowiez CA, Traer E, Stock W, Odenike O, Patel AA, Baer MR, Duong VH, Stein EM, Blum W, Vale CA, Curran E, Madanat YF, Olin RL, Schiller GJ, Nichols AD, Williams L, Heerema NA, Johnson MF, Chen TL, Marcus S, Martycz M, Stefanos M, Rosenberg L, DeGennaro LJ, Gruenbaum L, Burd A, Byrd JC, Druker BJ, Levine RL, Yocum AO, Mims AS, Zeidner JF. OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML. Blood. 2026 Jul 28:blood.2026034611. doi: 10.1182/blood.2026034611. Epub ahead of print. PMID: 42520193.
  40. Rocha Lima CMSP, Yothers G, George TJ, Hochster HS, Sanoff HK, Cohen DJ, Guthrie KA, Jacobs SA, Saeed A, Kopetz S, Colangelo LH, Freeman TJ, Cole SW, Khalil M, Devanna S, Zuckerman DS, Hong TS, Henry NL, Ganz PA, Blanke CD, Wolmark N, Overman MJ. COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer. J Clin Oncol. 2026 Jul 29:JCO2503052. doi: 10.1200/JCO-25-03052. Epub ahead of print. PMID: 42525921.
  41. Ji J, Sun CL, Dale W, Cohen HJ, Kim H, Katheria V, Baclig N, Zektser Y, Niknafs A, Margolis S, Lee C, Smith C, Sedrak MS. Early discontinuation of chemotherapy in older adults with early breast cancer: results from the prospective multicenter HOPE study. J Natl Cancer Inst. 2026 Jul 30:djag250. doi: 10.1093/jnci/djag250. Epub ahead of print. PMID: 42530890.
  42. Bailey AV, Frochen S, Kwan L, Siavoshi M, Haroldsen CL, Shelton JB, Rose B, Maxwell KN, Nickols NG, Yamoah K, Rebbeck TR, Schoen MW, Rettig MB, Vassy JL, Garraway IP, Iyer HS. A Comparison of Prostate Cancer Incidence and Mortality Rates in the Veterans Affairs Healthcare system and the Surveillance, Epidemiology, and End Results Program. Cancer Epidemiol Biomarkers Prev. 2026 Jul 30. doi: 10.1158/1055-9965.EPI-26-0248. Epub ahead of print. PMID: 42530444.
View the full list of Hematology Oncology publications